interquality wp 1 – incentives and payment models

25
InterQuality WP 1 – Incentives and Payment Models Robert Berenson, M.D. The Urban Institute Warsaw, 18-19 January 2011

Upload: lixue

Post on 24-Feb-2016

41 views

Category:

Documents


0 download

DESCRIPTION

InterQuality WP 1 – Incentives and Payment Models. Robert Berenson, M.D. The Urban Institute Warsaw, 18-19 January 2011. Proposal Objectives. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: InterQuality WP 1 – Incentives and Payment Models

InterQuality WP 1 – Incentives and Payment

ModelsRobert Berenson, M.D.

The Urban Institute Warsaw, 18-19 January 2011

Page 2: InterQuality WP 1 – Incentives and Payment Models

Proposal Objectives

• Comprehensive literature review on impact of incentives on clinical issues (quality), economic issues (costs), and equity in the areas of hospital care, outpatient care, integrated care and pharmaceutical care.

• Develop criteria for desirable payment models in these areas

• Support the development of generic and country-specific payment models

Page 3: InterQuality WP 1 – Incentives and Payment Models

Proposal Specification of Tasks

1 -- Literature and methodology review, definition development

2 -- Input from collaborative partners3 -- Comparative analysis of incentives and

payment models 4 -- Criteria development

Page 4: InterQuality WP 1 – Incentives and Payment Models

Some Definitional/Scope Issues

• The proposal equates the sectors identified (hosp., pharm., etc.) with “different patient groups.” Shouldn’t this be provider groups?

• Incentives tend to focus on financial incentives but we have suggested review of non-financial incentives as well. Very broad scope.

Page 5: InterQuality WP 1 – Incentives and Payment Models

Definitional Issues (cont.)

• Assume “outpatient care” refers both to institutions and professionals/clinicians. Whereas hospital care refers just to the institution. Can be confusing because some payment schemes combine professional and institutional payments

• What do we mean by integrated care? In US tends to refer to care across health care sectors but in Europe can mean integration with social services, e.g. housing.

Page 6: InterQuality WP 1 – Incentives and Payment Models

Definitional Issues (cont.)

• A common conceptual issue/error is thinking that financial incentives refers to marginal incentives – rewards and penalties – associated with performance against specific quality or other metrics while ignoring the incentives inherent in the basic payment scheme.

• The plan is to review the incentives in the basic payment schemes and consider P4P as supplemental incentives whose impact can vary in relation to the underlying payment scheme.

Page 7: InterQuality WP 1 – Incentives and Payment Models

Financial Incentives, Healthcare Providers and Quality ImprovementFrom The Health Foundation, London.

Authors -- Jon Christianson, U of Minnesota; Sheila Leatherman, U of North Carolina and London School of Economics; and Kim Sutherland, U of Cambridge, 2007 and updated

Page 8: InterQuality WP 1 – Incentives and Payment Models

From the Report

“Financial incentives… can be described as the influence that payments to organisations and individuals have on the health care services they deliver to consumers… In this review, we focus on explicit financial rewards or sanctions that are directed towards improving the quality of care delivered by organisations or practitioners to patients. However, these rewards or sanctions often are layered on top of or blended with payment approaches designed to affect service delivery in other ways.”

Page 9: InterQuality WP 1 – Incentives and Payment Models

Putting the Cart Before the Horse?

In my view the underlying payment approach provide the stronger incentives that influence provider behavior (organizational and individual) rather than the marginal incentives and should be the primary focus of analysis. (see accompanying paper provided)

Page 10: InterQuality WP 1 – Incentives and Payment Models

To Accomplish the Objectives (and Meet the Commitments)

I suggest some additional and revised steps and potentially additional useful products.

1 – Create a categorization of the alternative payment methods in the four sectors

2 – Identify attributes (theoretical incentives) of each payment method

3 – Perform required literature review4 – Identify gaps in the measures used in the lit review to

help WP25 – Develop the criteria for payment methods, which will

mostly be presented as pros and cons

Page 11: InterQuality WP 1 – Incentives and Payment Models

1.Categorization of Payment Methods

I am not sure at this time whether there are accepted typologies of payment models for each of our sectors. Probably for hospitals and physicians but not sure about outpatient facility and pharmaceuticals, and probably not for integrated care

Also, there is greater need to describe hybrid payment schemes that mixes and matches

Will be an early step based on review of literature syntheses and then review by consortium members for accuracy and completeness

Page 12: InterQuality WP 1 – Incentives and Payment Models

2. Attributes of Each Payment Method

It is useful to develop theoretical delineation of pros and cons of payment methods and then test empirically because there will be large data gaps in literature and yet payment methods need to be adopted and revised continually. Also this analysis should inform the fine-tuning of payment methods, how to guard against provider “misbehavior” and where to emphasize performance metrics. These attributes also involve considerations such as feasibility, potential for “gaming,” etc. and can be informed and modified as evidence comes in.

Page 13: InterQuality WP 1 – Incentives and Payment Models

Examples for Clinician Payment Methods

Page 14: InterQuality WP 1 – Incentives and Payment Models

FFS Attributes• Advantages

– Rewards activity, industriousness – Theoretically can target to encourage desired behavior– Implicitly does case-mix adjustment– Commonly used by payers and physicians

• Disadvantages– Can produce too much activity, physician-induced demand– Maintains fragmented care provided in silos – High administrative and transaction costs– What is not defined as reimbursable is marginalized– Complexity makes it susceptible to gaming and to fraud

Page 15: InterQuality WP 1 – Incentives and Payment Models

PPPM (Comprehensive or Global Payment)

• Advantages– Internalizes allocation of activity and costs to meet

needs– Direct incentive to restrain spending– Predictable and capped spending – Administratively simple (until address some of the problems)– Low transaction costs

• Disadvantages– May lead to stinting on care– Susceptible to cream-skimming– Incentive to cost shift to services outside the PPPM– Can’t specifically promote desired activity – May resist innovation/ new services

Page 16: InterQuality WP 1 – Incentives and Payment Models

Episode/Condition/Bundle/Case• Advantages

− internalizes incentives for efficiency within the episode− potentially aligns incentives across siloed providers− arguably, is an intermediate step on the way to real

integration• Disadvantages

− does not fundamentally alter incentive to generate units of service

− be careful about what you wish for, e.g. physician-hospital alignment without determination of appropriateness in a FFS environment

− currently, political challenges in bundling among providers− technically challenging (esp. for ambulatory care) – vagaries

of diagnosis (more episodes in Miami than Minnesota), bias to performance of a procedure in a case rate, sorting out where particular claims are assigned to

Page 17: InterQuality WP 1 – Incentives and Payment Models

Public Reporting and Pay-for-Performance (P4P)

• Advantages– provides a hybrid payment to mitigate disadvantages of pure

models; some natural blends – PPPM and under-service measures

– can start to actually reward desired performance, instead of rewarding volume of services produced

– can include measures of patient experience, which have been generally ignored in considerations of reformed payment approaches

• Disadvantages– underdeveloped measure set – especially for physicians – what gets measured gets done?– marginal incentives may be insufficient to counter basic

incentives in whatever base model it is superimposed over – contributes more administrative complexity

Page 18: InterQuality WP 1 – Incentives and Payment Models

2. Attributes of Each Payment Method (cont.)

Will be performed concurrently with the literature review and updated throughout the project -- and will need to be reviewed by the consortium, as these attributes are based not only on results from literature review but also from expert opinion to address gaps in evidence and to consider practical issues that are outside of impact on quality, costs and equity.

Page 19: InterQuality WP 1 – Incentives and Payment Models

3. Perform Literature Review

Method of Christianson et al. above“Electronic searches were performed by the

Centre fir Reviews and Dissemination at the University of York, with supplementary searches undertaken by the research team. Electronic searches of MEDLINE, EMBASE, Cochrane, DARE, EconLit. Also, AHRQ, OECD, WHO

Search strategy had 2 parts – 1st, retrieve systematic reviews using a wide range of search terms; 2nd, more limited # of search terms but a wider range of research designs

Page 20: InterQuality WP 1 – Incentives and Payment Models

Christianson, et al. method (cont.)

Define period of study, i.e., Jan 88 – Aug 06 and then extended through June 07.

Then very detailed process of retrieving and reviewing full articles and in every case writing an article summary using a standard abstract format. Reviewed by 2 team members

Majority of articles retrieved through this search process were from the US.

Page 21: InterQuality WP 1 – Incentives and Payment Models

3. Perform Literature Review (cont.)

Issues: Do we need this kind of thorough primary source

review across 4 (really 5) sectors and with need for much greater review of international, not just US, experience?

Can we rely more on secondary sources/ others’ reviews, including OECD, WHO and European Observatory?

Who here can provide advice on conducting formal lit reviews?

Page 22: InterQuality WP 1 – Incentives and Payment Models

4 – Identify gaps in the measures used in the literature review to help WP2

WP1 needs to work closely with WP2 because the literature on impact of payment incentives on quality, cost, and equity inherently requires identification of what metrics are used for the assessment.

From literature review, will identify methodological issues with use of various performance metrics and provide that separately to WP2.

Page 23: InterQuality WP 1 – Incentives and Payment Models

5 – Develop the criteria for payment methods

We proposed a set of criteria through a consensus process among the consortium members to be used in evaluation current and proposed payment schemes. These included considerations of feasibility, program integrity (i.e. gaming and fraud) as well as the primary end points of quality, cost and equity.

The assumption is that there is no “best” method because specific adoption will vary across health systems based on nature of health system, political culture, strategic considerations, etc.

Page 24: InterQuality WP 1 – Incentives and Payment Models

5 – Develop the criteria for payment methods (cont.)

Accordingly, there needs to be a consensus process across consortium members informed by the work on attributes and literature review, but including considerations of values and balancing objectives (quality, cost, equity, feasibility, etc.)

These might be better laid out as advantages and disadvantages rather than a ranking

Criteria can also be informed by health system experts in our countries and be updated throughout the three year process

Need feedback loop as WPs 3-6 evolve

Page 25: InterQuality WP 1 – Incentives and Payment Models

Time LineCategorization of payment schemes in Feb-March

– with need for consortium review and comment – by email

Develop first pass at “attributes”, literature review, and identification of measures for use by WP2 Feb – May, with distribution before meeting in Seattle in June

Finalize literature review, June – OctoberInitiate criteria development process June and

probably need a dedicated process for late summer/early fall, ideally in person (first draft due at 8 months – may lapse a little?)